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Abstract
Glioblastoma stem cells (GSC) are a significant cell model for explaining brain tumor recurrence. However, mechanisms
underlying their radiochemoresistance remain obscure. Here we show that most clonogenic cells in GSC cultures are
sensitive to radiation treatment (RT) with or without temozolomide (TMZ). Only a few single cells survive treatment and
regain their self-repopulating capacity. Cells re-populated from treatment-resistant GSC clones contain more clonogenic
cells compared to those grown from treatment-sensitive GSC clones, and repeated treatment cycles rapidly enriched
clonogenic survival. When compared to sensitive clones, resistant clones exhibited slower tumor development in animals.
Upregulated genes identified in resistant clones via comparative expression microarray analysis characterized cells under
metabolic stress, including blocked glucose uptake, impaired insulin/Akt signaling, enhanced lipid catabolism and oxidative
stress, and suppressed growth and inflammation. Moreover, many upregulated genes highlighted maintenance and repair
activities, including detoxifying lipid peroxidation products, activating lysosomal autophagy/ubiquitin-proteasome
pathways, and enhancing telomere maintenance and DNA repair, closely resembling the anti-aging effects of caloric/
glucose restriction (CR/GR), a nutritional intervention that is known to increase lifespan and stress resistance in model
organisms. Although treatment–introduced genetic mutations were detected in resistant clones, all resistant and sensitive
clones were subclassified to either proneural (PN) or mesenchymal (MES) glioblastoma subtype based on their expression
profiles. Functional assays demonstrated the association of treatment resistance with energy stress, including reduced
glucose uptake, fatty acid oxidation (FAO)-dependent ATP maintenance, elevated reactive oxygen species (ROS) production
and autophagic activity, and increased AMPK activity and NAD+ levels accompanied by upregulated mRNA levels of SIRT1/
PGC-1a axis and DNA repair genes. These data support the view that treatment resistance may arise from quiescent GSC
exhibiting a GR-like phenotype, and suggest that targeting stress response pathways of resistant GSC may provide a novel
strategy in combination with standard treatment for glioblastoma.
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Introduction
Glioblastoma (World Health Organization/WHO grade IV) is
the most common and aggressive type of primary malignant brain
tumor in adults, killing nearly every patient within two years.
Currently, the best standard treatment for newly diagnosed
glioblastoma is maximal safe surgical resection followed by
radiation treatment (RT) combined with concomitant and
adjuvant temozolomide (TMZ) [1]. Although patients whose
tumors have a methylated promoter for the gene encoding for O-
6-methylguanine-DNA methyltransferase (MGMT) are more
likely to benefit from the addition of TMZ to RT, they become
resistant to the treatment. The development of resistance suggests
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that there is a remnant of cancer cells possessing tumorigenic
capacity with extraordinary defense mechanisms, enabling them to
survive treatment.
Glioblastoma stem cells (GSC) have become a significant
experimental model for explaining tumor recurrence because they
possess a tumorigenic capacity [2–7], a highly migratory nature
[7,8], and a radiochemoresistant phenotype [9–11]. The definition
of GSC varies with the laboratory, but it is generally accepted that
they are a small subset of glioblastoma cells residing within the
tumor mass that expresses normal stem cell markers, are capable
of clonally growing as tumor spheres in vitro, and are able to
reconstitute a tumor in mouse brain that recapitulates the
histopathological features of the patient tumor from which the
GSC were derived. Multiple intrinsic mechanisms underlying
resistance to standard treatment in GSC have been proposed,
including preferential activation of DNA damage checkpoint
response and DNA repair pathway [9,12], expression of the
constitutively active Notch/PI3K/Akt, Wnt, and IGFBP2 signal-
ing pathways [13–15], and high expression of anti-apoptotic
proteins and drug efflux transporters [16–18]. However, some
authors did not find different DNA repair mechanisms in stem and
non-stem glioma cells [19,20].
The development of radioresistance or chemoresistance may be
considered a cell survival adaptive response (AR) or a hormetic
response (HR), where cells become more resistant to stress damage
by prior exposure to a low dose of ionizing radiation (IR) or other
DNA-damaging agents [21,22]. AR can also be induced by ROS,
which are generated in cells during cellular respiratory metabolism
and/or after exposure to IR, and produce low levels of
macromolecular damage which includes oxidative stress [23].
Several defense mechanisms underlying radioadaptive protection
have been postulated, including enhancement of free radical
detoxification, activation of DNA repair systems, induction of new
proteins for repair and maintenance, and increase in anti-oxidant
production [23–25]. Similar to AR/HR in principle, protective
effects can be induced by caloric/dietary restriction (CR/DR), a
potent nutritional intervention that has been shown to extend the
lifespan of multiple species and model organisms for slowing the
aging process down, and protect against age-related diseases in
humans [26,27]. Many different mechanisms have been proposed
to promote the anti-aging/anti-senescence effects of CR, including
disruption of the insulin/insulin-like growth factor-1 (IGF-1)
signaling (IIS) pathway [28], attenuation of TOR signaling [29],
growth retardation [30], suppression of inflammation [31],
mitochondrial hormesis [32], enhancement of autophagy [33],
activation of SIRT1 (silent mating type information regulation 2,
homolog 1)- PGC-1a (Peroxisome proliferator-activated receptor
gamma coactivator-1 alpha) signaling axis [34,35], enhancement
of DNA repair [36,37], and the hormetic effects of mild stress
[38,39]. Although the effectors which directly contribute to the
survival and longevity-enhancing effects of CR are not completely
understood, the collective actions of these pathways seem to point
towards the generation of metabolic adaptations to nutritional
stress, leading to slowed cell growth and activated repair and
maintenance networks.
In this study, we explored the potential mechanisms underlying
treatment resistance of glioblastoma. We isolated and character-
ized tumorigenic GSC clones that survived radiochemotherapy.
We found that under no glucose deprivation condition, these
resistant GSC clones favor the FAO pathway and express a GR-
like phenotype, and exhibit reduced glucose uptake, promoted
lipid metabolism in mitochondria, increased formation of ROS,
and enhanced autophagy, AMP-activated protein kinase (AMPK)-
SIRT1 signaling, and upregulated genes associated with global
DNA repair activity. These findings could impact the design of
more effective therapies aiming to prevent tumor recurrence.
Materials and Methods
Glioblastoma sphere cultures
Glioblastoma tumor specimens were obtained from patients
who underwent surgery at Ronald Reagan UCLA Medical
Center. All samples collected were under patients’ written consent,
and were approved by the UCLA Institutional Review Board (IRB
# 0304-053). GSC culture lines were established from fresh
tumors. GSC culture lines were established from fresh tumors.
Briefly, tumors were enzyme-digested and washed, followed by red
blood cell lysis of the pellet. Dissociated tumor cells were plated
and maintained in serum-free DMEM/Ham’s F-12 supplemented
with 20 ng/ml epidermal growth factor (EGF, Sigma), 20 ng/ml
basic fibroblast growth factor (bFGF, Millipore), 10 ng/ml
leukemia inhibitory factor (LIF, Millipore), and 1x B27 without
vitamin A (Invitrogen). The tumor spheres were dissociated and
replated at clonal density and continually passaged until the
clonogenic cells were stably maintained. CD133+ cells were sorted
from the cultures by anti-CD133/1-phycoerythrin and flow
cytometry and used as cell sorce to re-initiate GSC culture lines.
The GSC culture lines used in this study were derived from three
glioblastoma tumors; D431 and S496 were derived from patients
whom received radiation and chemotherapy prior to their
recurrence and re-operation, and E445 was obtained prior to
treatment. Based on prediction set of 595 gene hierarchical
clustering by Freije et al., which subclassifies glioblastomas
corresponding to four clinical relevant subtypes as categorized
by The Cancer Genome Atlas (TCGA) Research Network
[40,41], the D431 tumor was assigned to MES subtype due to
overexpression of extracellular matrix components and regulators.
Meanwhile, S496 and E445 were assigned to PN subtype due to
overexpression of genes involved in proliferation/mitosis and
neurodevelopment, highlighting the poor prognosis and lack of
therapies in all three cases.
Isolation of treatment-resistant clonogenic clones and
clonogenic survival assay
Dissociated GSC spheres were seeded in 60615 mm gridded
culture dishes on day 0 at 900 cells/dish in 2 ml stem cell culture
media and incubated overnight. Cells were irradiated in 3
fractions of 4 Gy, at a dose rate of 0.7– 0.8 Gy per minute
(Gulmay Medical) on days 1, 4, and 7. This radiation dose
regimen is approximately 1/5 of the dose used in clinical
treatment. For chemoradiation, 5 mM TMZ was added to cell
cultures 2 hrs before the first dose of 4 Gy RT and after each RT
fraction, while simultaneously replacing half of the medium with
fresh medium (concurrent treatment). After a 2-day break, 10 mM
TMZ was added for an additional 4 days after a 2-day interval
(adjuvant treatment). After the course of fractionated irradiation
with and without TMZ was completed, the surviving cell
populations that formed colonies were counted on day 14 (Figure
S1). Single colonies derived from non-treated plates and treated
plates were picked up using a pipette, and individually expanded
for further characterization.
Proliferation assay for clonogenic clones
The proliferative activity of clonogenic clones were determined
by a 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS/PMS) colorimetric assay
according to the manufacturer’s instructions (Promega). Cells
Stress Response Pathways in Glioblastoma Stem Cell
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were incubated for 72 hours and the absorbance was measured at
490 nm.
Cell cycle analysis of 5-bromo-2-deoxyuridine (BrdU)
labeled cells
A BrdU pulse-chase time course was conducted for measuring
cell turnover using APC BrdU Flow Kit (BD pharmingen). Briefly,
cells were pulsed with BrdU (10 mM) for 1 hr. The cells were
washed and incubated further at 37uC for 3 h and 6 h, after which
the cells were harvested, fixed, and permeabilized with BD
Cytoperm Permeabilization Buffer Plus. Cells were then incubated
with DNase to expose incorporated BrdU, followed by addition of
APC-conjugated anti-BrdU antibody and 7-amino-actinomycin
(7-AAD). The cell cycle analysis of BrdU+ cells for each time point
was acquired on a BD FACSVerse system.
Tumor formation assay and histopathological analysis
The tumorigenicity of sensitive and resistant clones was
determined by injecting 105 live cells in a volume of 3 ml into
NOD.CB17-Prkdcscid/J mice intracranially (i.c.). Mice were
sacrificed if neurological symptoms started to show. Tumor tissues
were collected and subjected to hematoxylin-eosin (H-E) staining
for histopathological analyses. All animal work in this study was
approved by UCLA Institutional Animal Research Committee
(ARC # 2005-063-22).
Microarray procedures, data analysis and gene
annotation
Molecular profiling of sensitive and resistant GSC clones was
performed using standard Affymetrix protocols and hybridized to
Affymetrix GeneChip U133 Plus 2.0 Array as described previously
[40]. The group comparisons were performed in dChip and
samples were permuted 100 times to assess the false discovery rate
(FDR). Probe set signals that were $2-fold in resistant versus
sensitive group and with a pairwise t-test (P,0.05) were selected.
All microarray CEL files analyzed in this study are accessible from
the Gene Expression Omnibus (GEO) (Series Accession number:
GSE46531). Functional annotation of individual gene was
obtained from NCBI/Entrez Gene (http://www.ncbi.nlm.nih.
gov/sites/entrez), Uniprot (http://www.uniprot.org/), informa-
tion hyperlinked over protein (http://www.ihop-net.org/), neXt-
Prot (http://www.nextprot.org/), BioGraph (http://biograph.be/
about/welcome) and the published literature in PubMed Central
(http://www.ncbi.nlm.nih.gov/pubmed).
Semi-qt reverse transcriptase polymerase chain reaction
(RT-PCR) analysis
Total RNA was extracted from cells using an RNeasy kit
(QIAGEN). Two micrograms of RNA from each sample were
transcribed to cDNA using a Taqman RT Reagent Kit (Applied
Biosystems). PCR was performed, using 5 ml cDNA equivalents to
100 ng total RNA and was carried out by using SYBR Green
PCR Core Reagents (Applied Biosystems). The reactions were
cycled 30 times [50uC for 2 minutes and 95uC for 10 minutes
(94uC for 15 seconds, 58–60uC for 1 minute, and 72uC for 1
minute) x 30 cycles]. PCR products (5 ml) were electrophoresed on
2% agarose gel. The primer sequences and expected size of PCR
products are described in Table S1.
siRNA transfection
A reverse transfection protocol was performed to deliver gene-
targeted siRNA (Ambion) or non-silencing control siRNA
(Ambion) into cells. Briefly, a transfection complex was prepared
by diluting siRNA in 10 ml OPTI-MEMI (Invitrogen) then adding
10 mL OPTI-MEMI containing 0.3 mL Lipofectamine RNAi-
MAX transfection reagent (Invitrogen). This complex was then
added into each well in a 96-well plate followed by seeding 6000
GSCs in 100 mL media to give a final siRNA concentration of
30 nM in each well. Targeted gene silencing was determined
72 hrs after transfection by qtRT-PCR, using Power SYBRH
Green Cells-to-CTTM Kit (Ambion).
Western blot analysis
20 mg protein from each sample were separated on 10% SDS-
PAGE (Bio-Rad) and transferred onto a PVDF membrane. The
blots were incubated with the primary antibodies overnight at 4uC.
The following primary antibodies were used: Rabbit anti-human
p53, phospho-p53 (Ser20), AMPKa, phospho-AMPKa (Thr172),
Akt, phospho-Akt (Thr308) (all at 1:1000), and b-actin (1:2000,
Cell Signaling). The blots were washed and incubated with
horseradish peroxidase-conjugated anti-rabbit IgG for 1 h. Then,
the blots were washed again, incubated with Pierce Supersignal
ECL substrate, and exposed to X-ray films.
Functional assays of cell metabolism
ATP levels were determined using a luciferin–luciferase-based
bioluminescence assay (Molecular ProbesH ATP Determination
Kit, Invitrogen) according to the manufacturer’s instructions.
104 cells/well were plated in 96-well plates and exposure to 2-
deoxyglucose (2-DG), histidine, or Etomoxir (all from Sigma) at
the concentrations indicated in the figures and incubated for 45
minutes. Luminescent intensity was measured by a SpectraMax
M5e Multi-Mode Microplate Reader (Molecular Devices).
2-(N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino)-2-deoxyglucose,
a fluorescently-labeled deoxyglucose analog (2-NBDG, Cayman
Chemical), was used as a probe for detecting glucose uptake by
cells. Cells were seeded at a concentration of 46105 cells/ml/
well in a 6-well plate, in duplicate, and incubated overnight at
37uC. Cells were washed twice and incubated with 10 mM 2-
NBDG in glucose-free culture media in the presence of 1 mM
insulin for 20 min. Cells cultured in media without 2-NBDG
were used as negative control. Cells were washed twice prior to
flow cytometric analysis.
2979-dichlorofluorescein diacetate (DCF-DA) (Sigma) was used
to detect reactive oxygen species (ROS) in cells. 46105 cells/ml/
well in a 6-well plate were pretreated with or without 5 mM Tiron,
an ROS scavenger (Sigma), at 37uC for 30 minutes. Cells were
washed and incubated with 20 mM DCF-DA in PBS at 37uC for
30 min, then washed twice with PBS. Cells were resuspended with
PBS containing 500 mM H2O2 and subjected to flow cytometric
analysis.
Intracellular oxidized nicotinamide adenine dinucleotide
(NAD+) were determined by NAD+/NADH cell-base assay kit
(Cayman Chemical) according to the manufacturer’s instructions.
104 cells/well were plated in 96-well plate for overnight. Culture
media was removed and cells were lysed. After centrifugation,
100 ml supernatant and titrated standards were transferred to a
new plate followed by adding 100 ml reaction solution. Absorbance
of each sample was measured using a microplate reader at a
wavelength of 450 nm.
The endogenous levels of phosphorylated AMPK (pAMPK a/
Thr172) and phosphorylated Akt (phospho-Akt/Thr308) in cells
were determined by PathScanH Phospho-AMPKa and Phospho-
Akt Sandwich ELISA Kits (Cell Signaling), respectively, according
to the manufacturer’s instructions. 70 mg protein from each
sample was used in the assay. Absorbance of each sample was
measured at a wavelength of 450 nm.
Stress Response Pathways in Glioblastoma Stem Cell
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Autophagy was determined by LysoTrackerH Red DND-99
(Invitrogen). The quantitation was based on a correlation between
autophagic activity and overall lysosomal acidity. Cells were
incubated with prewarmed fresh media containing 75 nM probes
at 37uC for 1 hr. After incubation, the stained cells were washed
and resuspended with 500 ml PBS, and analyzed by flow
cytometric analysis.
Exome sequencing
To detect DNA changes in coding regions at single base
resolution and regional copy number changes, we performed
exome capture of sensitive and resistant GSC clones, using the
SureSelect Human All Exon Kit (Agilent). The samples were
tagged with a unique barcode and sequenced using a paired-end
protocol on a portion of a lane of an Illumina HiSEQ instrument,
to generate an average of 100x base coverage over the exome of
unique independent reads sufficient for high-quality diploid
genome sequencing. Generated reads were aligned to human
reference genome using Novoalign (www.novocraft.com), sorted,
and stored in bam (binary SAM) format. Reads corresponding to
PCR duplicates were marked with the Picard MarkDuplicates tool
(picard.sf.net), and the Broad Institute’s Genome Analysis Toolkit
(GATK) was used for recalibrating base quality recalibration,
indels realignment, and to call and annotate variants. Tools from
GATK, along with custom scripts and tools, were used to select
treatment-sensitive and treatment-resistant clone-unique muta-
tions and to find commonly mutated sites, genes, and pathways
among the different clones. Copy number variation (CNV) and
loss of heterozygosity were analyzed by ExomeCNV.
Statistical analysis
Each experiment was set up in duplicate or triplicate, and
repeated at least twice. Data were expressed as means 6 SD and
analyzed using one-way ANOVA tests, depending on homogene-
ity of variances. All P-values were two-sided, and values lower than
0.05 were considered significant. SPSS v13.0 for Windows
software was used for all statistical analyses.
Results
A minority of clonogenic cells in GSC cultures resist
radiation and radiochemotherapy
We have previously established and characterized several
patient tumor-derived CD133+ GSC culture lines [7,42]. The
CD133+ GSC cells purified from tumor sphere cultures express
both radial glial and neural crest cell developmental genes and are
capable of clonal self-renewal and division to produce CD1332
fast-growing progeny that are morphologically heterogeneous
revealed by differences in cell sizes and shapes, which form the
major cell population within tumor spheres [7]. We found that
long-term passaged GSC lines typically contain 3-30% CD133+
cells even initiated by purified CD133+ cells, and suggested that
slow self-renewal and fast proliferative division/differentiation
naturally occur during passaging in serum-free media containing
stem cell growth factors [7]. In our hands, besides purified
CD133+ GSC from tumor sphere cultures, most clonogenic cells
repopulated from CD133+ GSC cultures (e.g. single cell-derived
colonies/spheres) could reconstitute a tumor in mouse brain.
Moreover, the tumor xenograft initiated by these single-cell
derived tumor spheres/colonies could be maintained by serial
passage in the animals, suggesting patient tumor-derived CD133+
tumor sphere cultures may contain heterogeneous population of
stem-like cells with tumor-initiating capacity. To understand the
mechanisms underlying glioblastoma resistance to RT or
RT+TMZ, we isolated treatment-resistant clonogenic cells from
three established CD133+ GSC cultures [7,42] by treating them
with fractionated RT (4 Gy/fraction, 3 fractions per week for
1 wk) or concomitant RT plus TMZ (5 mM) followed by adjuvant
TMZ (10 mM) as described in Materials and Methods and Figure
S1. The clonogenic survival assays showed that untreated (or
pretreated) cultures seeded with 900 cells (derived from GSC
cultures) per 60 mm diameter dish exhibited 5-14% clonogenic
efficiency (CE) when colonies of more than 50 cells were counted
on day 14, whereas RT with or without TMZ treatment caused a
massive killing of cells within two to three fractions, and no
colonies with more than 50 cells were counted (Figure 1A, a–c).
However, we have observed a few surviving single cells which have
slowly grown into colonies (all had fewer than 20 cells per colony
on day 14 with a survival rate of 0.3-0.95%) (Figure 1A, d).
Cultures treated with RT+TMZ had a lower CE than those
treated with RT alone. These clonogenic survivors gradually grew
into larger colonies (Figure 1B) and were picked and expanded
individually, and designated as treatment-resistant GSC clones or
resistant clones. In parallel, selected large colonies (.50 cells/
colony) were picked up from the untreated plates on day 14 after
seeding and were designated as treatment-sensitive GSC clones or
sensitive clones. Cells treated with 10 mM TMZ alone showed
similar CE to that of the untreated cells and were not recruited for
a follow-up study.
Treatment-resistant GSC clones gave rise to both
resistant and sensitive clones and repeated treatment
further promotes their enrichment
Next, we examined whether treatment-selected, single cell-
derived resistant clones were more clonogenic than single-cell-
derived sensitive clones and whether repetitive treatment results in
further enrichment of resistant clones. The clonogenic assay
showed that the cells reseeded by resistant clones contained
significantly higher numbers of clonogenic cells than those
repopulated from sensitive clones (Figure 2A). Clonogenic cells
grown from resistant clones however, were still sensitive to a
second cycle of RT treatment (TC2); but, more cells survived and
unlike in the first cycle (TC1), formed colonies of .50 cells at day
14 with a clonogenic survival rate (CSR) of 1.2-3% (Figure 2B,
2C). Moreover, the number of small colonies (10–50 cells/colony)
were significantly increased (6–15 fold) (Figure 2B, 2C) after the
second treatment cycle that gradually grew into large colonies
within 3–4 weeks. These data thus indicate that although RT or
RT+TMZ treatment could still deplete the majority of cell
population grown from resistant clones, treatment also simulta-
neously selected for a small number of resistant clones, while
further treatment cycles can increasingly expand them. These
observations also demonstrated a hierarchy of self-renewing
resistant clones in the tumor sphere cultures capable of generating
heterogeneous population containing resistant clones, sensitive
clones, and non-clonogenic cells (Figure S2). The cellular diversity
in resistant clone-derived populations apparently exhibited differ-
ential sensitivity to the treatment.
Treatment-resistant GSC clones are slow-cycling, stem-
cell like, tumor-initiating cells
Since both sensitive and resistant clones are clonogenic and
were selected from tumorigenic bulk GSC cultures, we tested
whether treatment resistance is associated with expression of stem
cell markers. The qtRT-PCR analysis revealed that mRNA levels
of CD133, SRY (sex determining region Y)-box 2 (SOX2) and
musashi homolog 1 (MSI1) (except S496-RT) were upregulated in
Stress Response Pathways in Glioblastoma Stem Cell
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resistant clones when compared to sensitive clones, but not nestin,
SOX4, or maternal embryonic leucine zipper kinase (MELK)
(Figure 3A).
Correspondingly, resistant clones exhibited slightly less prolif-
erative activity in culture as determined by short-term proliferation
assays (72 hrs) (Figure 3B). To determine whether resistant clones
are indeed slow-cycling cells when compared to sensitive clones,
we performed a BrdU pulse-chase time course at 3-hr and 6-hr
time points for measuring progression of BrdU-labeled cells
through the cell cycle (Figure 3C). The data indicated that for the
D431 cells at the 6-hr time point, 55.9% cells in sensitive clones,
30.3% cells in RT-resistant clones, and 35.0% cells in RT+TMZ-
resistant clones have completed a cell cycle. For the S496 cells at 3-
hr time point, 61.6% cells in sensitive clones, 48.9% cells in RT-
resistant clones, and 6.1% cells in RT+TMZ-resistant clones have
completed a cell cycle. For the E445 cells at 3-hr time point,
30.7% cells in sensitive clones, 2.1% cells in RT-resistant clones,
and 23.2% cells in RT+TMZ-resistant clones have completed a
cell cycle. Thus, resistant clones are slow-growing when compared
to sensitive clones.
To test whether treatment-sensitive and treatment-resistant
clones possess tumorigenic capacity, 26105 cells derived from
sensitive clones and resistant clones were stereotactically injected
into the brains of SCID mice. Mice which received cells derived
from sensitive clones (18/18), RT-resistant clones (17/18), or
RT+TMZ-resistant clones (16/18) all developed tumors, but the
growth of RT+TMZ-resistant clones was significantly delayed
when compared to that of sensitive clones (p = 0.0015) or RT-
resistant clones (p = 0.0376) (Figures 4A, 4B). Although tumor
growth from RT-resistant clones was delayed compared to tumor
growth from sensitive clones, the delay did not reach statistical
significance (p= 0.0659). The H-E staining of xenograft tumors
initiated by sensitive or resistant clones all demonstrated invasive
growth of gliomas with diffuse infiltration into the surrounding
tissue and vessels, and recapitulated the histopathological features
of human glioblastoma (Figure 4C, a-r). Clonogenic tumor cells
cultured from xenografts initiated by resistant clones can reinitiate
tumors in new hosts in a series of transplants (data not shown),
confirming the characteristics of tumor stem cells in resistant
clones.
Molecular signatures reveal defensive strategies of
treatment-resistant GSC clones are mainly associated
with responses of reduction of glucose usage and
activation of cellular and genomic maintenance and
repair pathways
To explore the differential molecular properties allowing
resistant clones to overcome or adapt to deadly radiochemother-
apy, we performed a comparative high-density microarray
analysis. We first determined the common genes that are
overexpressed in RT-resistant clones and RT+TMZ-resistant
clones when compared to group of sensitive clones. Six sensitive
clones (n = 3 patients, 2 clones per patient), 3 RT-resistant clones
(n = 3) and 3 RT+TMZ-resistant clones (n = 3) were used for the
analysis. Fifty-three informative genes were eluted with a FDR of
Figure 1. Cells repopulated from tumor-derived clonogenic cells are sensitive to RT or RT+TMZ treatment; only a few slow-growing
clonogenic cells can survive and regain their self-renewal capacity. A. Dissociated cells from GSC cultures derived from three patients’
tumors as indicated were plated in culture dishes at clonal density of 900 cells/2 ml/60 mm dish. Cells were incubated for overnight and subjected to
treatment as described in Figure S1. Untreated cells (UT) or treated with TMZ alone (10 mM every 3 days) served as control. Colonies that contained at
least 50 cells were counted on day 14 in all dishes (a-c) while small colonies that contained at least 6 cells were also counted in plates treated with RT
and RT+TMZ (d). Data represent mean values6 SD of triplicate dishes. B. Light-microscopic morphology of clonogenic survivors after treatment. Few
single cells survived treatment (a–c, j–l) (days 2–3) and slowly regained self-repopulating capacity (d–f, m–o) (days 14–21), (g–i, p–r) (days 25–30).
doi:10.1371/journal.pone.0080397.g001
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,0.1%, segregating the 2 groups (Table 1). Notably, many of the
identified genes are involved in multiple functions or serve similar
functions. The overall gene expression profile revealed a complex
of interconnected defense strategies highlighting the blocking of
IIS, decreased glucose uptake, augmentation of lipid catabolism,
activation of oxidative stress responses, suppression of growth,
differentiation and inflammation, stimulation of angiogenesis,
migration, anti-apoptosis, and amplification of cellular and DNA
maintenance and repair activities.
Evidently, a series of genes functioning in suppressing glucose
uptake, inhibiting insulin/Akt signalling, and limiting glycogen
breakdown (ENPP2, TXNIP, EGR1, SSFA2, IL-6ST, PLD3,
PPP2R1A, PPP1R3C) were upregulated in resistant clones and
suggest resistant clones exhibit a GR- and insulin-resistant-like
phenotype. The upregulation of genes with functions associated
with autophagy, lipid catabolism, and detoxification of lipid
peroxidation products (ENPP2, ALDH3A2, PLD3, OSBPL8)
further imply that resistant clones may use FAO as a major
anaplerotic input to keep the tricarboxylic acid (TCA) cycle
functioning for energy when the glycolysis pathway is limited. The
overexpression of these genes also serves as an indication of the
oxidative stress response of cells (TXNIP, EGR1, PLD3,
SLC38A1), especially TXNIP, which is not only a potent negative
regulator of glucose uptake and utilization, but also binds and
inhibits thioredoxin, and thereby can induce oxidative stress.
As anticipated, molecular signatures of resistant clones were
highly enriched with genes that promote genomic stability and
cellular/cytoskeletal integrity. These genes address DNA damage
response (DDR) (SUPT16H, ZC3H11A, C5orf24, MATR3),
activation of cell-cycle/spindle checkpoints (SUPT16H, TPR),
double-strand break (DSB) repair (SUPT16H, TPR, DHX9,
MATR3, PPP2R1A, FOLR1), nucleotide excision repair
(RAD23A), maintenance of telomere repeats (TPR, HNRPA3),
stabilization of the folded structure of the ribosomal RNA
(RPS20), the collagen fibrils and elastin integrity (MFAP4,
FBN1, LOX), and maintenance of cytoskeleton organization and
mitochondrial function (TPM4, PDLIM5, MAP4, PRKCI,
RAB2A, RASSF8). Moreover, activation of genes associated with
endoplasmic reticulum (ER)-associated unfolded protein response
(HSP90B1), lysosome biogenesis (ENPP2), the ubiquitin-proteaso-
mal pathways (UPP) (UBA6, RAD23A) and autophagic-lysosomal
system (ALP) in resistant clones support the view that these cells
are reacting to stress. The gene profiles also portrayed resistant
clones an anti-apoptotic (MALAT1, ENPP2, COL6A2, IL6ST,
MATR3, RPS11, PRKCI, MOBKL1B, PPP2R1A), anti-inflam-
matory (EPRS), migratory (MALAT1, ENPP2, COL6A2, IL6ST,
VEGFA, NFIX, FMNL2, PPFIBP1, ACTR2, RASSF8), and
angiogenic phenotypes (ENPP2, IL6ST, VEGFA, AGGF1). Their
quiescent nature is evidenced by upregulation of a series of genes
with a role in anti-growth, tumor suppression, anti-development,
Figure 2. Cells expanded from treatment-resistant GSC clones contain more clonogenic cells than those of treatment–sensitive GSC
clones and repeated treatment further promoted the expansion of resistant clones. A. The clonogenic efficiency was determined in cells
populated by resistant and sensitive clones, using limiting dilutions. Data represent mean values 6 SD of triplicate wells. *p,0.05 versus sensitive
clones. B. Clonogenic efficiency was determined in resistant clone-derived cells which underwent a second treatment cycle (TC2). Colony counts were
performed on day 14. Data represent mean values6 SD of triplicate dishes. *p,0.05 versus treatment cycle 1 (TC1). C. Light-microscopic morphology
of colonies repopulated by resistant clones recovered from a second treatment cycle of RT (a–f) (day 14) and RT+TMZ (g–l) (day 14).
doi:10.1371/journal.pone.0080397.g002
Stress Response Pathways in Glioblastoma Stem Cell
PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e80397
and anti-differentiation (TXNIP, LOX, NBPF, ATP13A3,
RASSF8, PDLIM5, PRRG4, BAT2D1, MOBKL1B, PPP2R1A,
RPL38, SF3B1). The differential gene expression in sensitive and
resistant clones was confirmed by qtRT-PCR analysis (Figure S3).
Similar molecular signatures were also detected when the
comparison was performed against RT-resistant clones or
RT+TMZ-resistant clones respectively (Table S2, Table S3),
implicating they may use similar pathways to achieve their
protective phenotype.
In order to test whether these upregulated genes have defensive
functions, which contribute to the protective properties of resistant
GSC clones, cells grown from resistant clones were pretreated with
siRNA targeting selected signatures prior to receiving RT or
RT+TMZ. As anticipated, cells derived from resistant clones
treated with siRNA negative control with or without RT (4Gy x 3)
all regain grow activity, while on-target knockdown of a series of
selected genes associated with metabolic transformation and stress
responses combined with RT treatment have resulted in the loss of
cellular integrity (Figure 5A, 5B). Notably, effective treatment
Figure 3. Treatment-resistant GSC clones are slow-cycling cells express upregulated stem cell markers. A. Total RNA of sensitive clones
and resistant clones were extracted. The mRNA expression levels of indicated stem cell-associated genes were analyzed by semi-qtRT-PCR with
specific primers. b-actin was used as an internal control gene. B. Proliferative activity of cells populated by resistant clones and sensitive clones was
determined by 3-day MTS/PMS cell proliferation assays. Data represent mean values 6 SD of triplicate measurements. C. Sensitive clones and
resistant clones were pulsed with 5-bromo-2-deoxyuridine (BrdU) for 1 hr, and cell cycle of BrdU+ cells was analyzed 3 hrs and 6 hrs after BrdU
pulsing. Cell cycle phases were defined by 7-amino-actinomycin (7-AAD) staining intensities.
doi:10.1371/journal.pone.0080397.g003
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could also be achieved when combined with lower dose RT (0.5Gy
x 3), indicating resistant clones have lost protective properties
against treatment. Moreover, knockdown of selected genes alone
without RT could also induce cell death and suggest that some of
the molecular signatures may not only serve as defensive
properties, but also serve as essential factors for maintaining cell
survival (Figure 5A). Similar results were obtained when treatment
was combined with RT+TMZ (data not shown).
Treatment-resistant GSC clones use FAO pathway to
maintain intracellular ATP levels and exhibit higher levels
of oxidative stress compared to treatment-sensitive GSC
clones
Based on the molecular signatures of resistant clones, we
hypothesized that resistant clones are in a ‘‘GR’’ status and lipid
catabolism has become a major energy source. To test this
hypothesis, we determined the intracellular ATP production in
resistant clones in the presence of 1) 2-DG, an inhibitor of glucose
uptake and glycolysis, 2) L-histidine, an inhibitor of mitochondrial
glutamine transport, or 3) Etomoxir, an inhibitor of mitochondrial
carnitine palmitoyltransferase I (CPT-1) which blocks FAO, and
compared results with those of sensitive clones in the same
condition. Blocking glucose uptake or glutamine transport partially
decreased ATP production in only sensitive clones, not resistant
clones, whereas inhibiting the FAO pathway altered ATP levels in
both sensitive and resistant clones (Figure 6A). Altered ATP levels
in sensitive clones led to reduced cell growth activity and colony
size as compared to those without treatment (Figure 6B). In
contrast, major cell death was only observed in Etomoxir-treated
resistant clones while no obvious effects were seen in the other two
conditions (Figure 6B). The glucose uptake assay further
confirmed reduced glucose uptake by resistant clones under
insulin stimulation (Figure 6C). This reduced glucose usage is not
likely mediated by long-term culturing in glucose/insulin-contain-
ing media since both sensitive and resistant clones were cultured
under the same condition and passages. Moreover, attenuated
AKT activity was determined in resistant clones when compared
to that of sensitive clones (Figure 6D), indicating resistant clones
are less dependent on glucose, and that FAO becomes a crucial
bioenergetic pathway for maintaining them. These data also
Figure 4. Treatment-resistant GSC clones exhibited a delay in tumor formation compared to those of treatment-sensitive GSC
clones. A. 26105 cells derived from treatment-sensitive clones, RT-resistant clones, and RT+TMZ-resistant clones were stereotactically injected into
the brains of SCID mice and days required for developing neurological signs by tumor growth in each mouse were recorded. Data represent mean
values 6 SD of indicated numbers of animals that have developed tumors. *p,0.05 versus RT+TMZ-resistant clones, **p,0.001 versus treatment-
sensitive clones. B. Representative macrophotographic image of glioma xenografts initiated by treatment-sensitive clones, RT-resistant clones and
RT+TMZ resistant clones that are growing in intracranial site. C. Representative hematoxylin and eosin (HE) staining of xenograft tumors. Brain tissues
from mice injected with either treatment-sensitive or treatment-resistant clones display invasive growth of gliomas and exhibits histopathological
features of human glioblastoma, including hypercellularity (Figure 4C, a, g, m), hyperchromatism (Figure 4C, b, h, n), pleomorphism (Figure 4C, c, i, o),
mitosis (Figure 4C, d, j, p), vascular endothelial hyperplasia (Figure 4C, e, k, q), and oligodendroglial components (Figure 4C, f, l, r). Magnification, 20X
and 40X as indicated.
doi:10.1371/journal.pone.0080397.g004
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Table 1. Molecular signatures and defense profiles of treatment-resistant glioblastoma stem cell clones.
Gene Name and Gene Symbol Fold Change P-Value Functional Involvement
MALAT1: metastasis associated lung adenocarcinoma
transcript 1
14.38 0.002085 antiapoptosis; migration; invasion; metastasis
ENPP2: ectonucleotide pyrophosphatase 2 10.98 0.019869 insulin resistance; lysosome biogenesis; antiapoptosis; cell
migration; angiogenesis
TXNIP: thioredoxin interacting protein 8.92 0.049541 blocking glucose uptake; oxidative stress; antigrowth
SUPT16H: suppressor of Ty 16 homolog (S. cerevisiae) 6.75 0.000119 histone chaperon; DDR; checkpoint activation; DSB repair;
transcription
EGR1: early growth response 1 6.29 0.020384 impaired insulin/akt signaling; reduced glucose uptake;
induction of sirt1 expression; autophagy
SSFA2: sperm specific antigen 2 6.22 0.008552 reduce glucose uptake; reduce metabolic rate; structural
integrity
COL6A2: collagen, type VI, alpha 2 5.52 0.009504 antiapoptosis; cell migration and adhesion
IL6ST: interleukin 6 signal transducer (gp130) 5.46 0.000039 cell migration; antiapoptosis; suppress insulin/akt signaling;
angiogenesis
EPRS: glutamyl-prolyl-tRNA synthetase 5.42 0.000664 translational control of inflammatory genes
MFAP4: microfibrillar-associated protein 4 5.34 0.027521 prevention of ECM degradation and aggravated elasticity
VEGFA: vascular endothelial growth factor A 5.30 0.011344 angiogenesis; vasculogenesis; endothelial cell growth and
migration
NFIX: nuclear factor I/X 5.14 0.006796 astrogenesis/gliogenesis; adhesion, migration and invasion
ALDH3A2: aldehyde dehydrogenase 3 family, member A2 5.01 0.011524 detoxification of lipid peroxidation product; suppress ER stress;
oxidizes aldehydes to fatty acid
FBN1: fibrillin 1 4.52 0.028724 structural support in microfibrils that form elastic fibers
ZC3H11A: zinc finger CCCH-type containing 11A 4.48 0.000062 phosphorylated upon DNA damage recognized by
ATM and ATR
C5orf24: chromosome 5 open reading frame 24 4.43 0.000421 phosphorylated upon DNA damage recognized by
ATM and ATR
PLD3: phospholipase D family, member 3 4.33 0.004337 lipid catabolism; block insulin/Akt signaling; oxidative stress;
cell survival
FMNL2: formin-like 2 4.33 0.035379 epithelial-mesenchymal transition; cell motility and invasion
TPR: translocated promoter region (to activated MET) 4.10 0.013417 DSB repair; telomere maintenance; recruitment of spindle
checkpoints
PPFIBP1: PTPRF interacting protein, binding protein 1 4.01 0.009418 maintain lymphatic vessel integrity; cell adhesion, migration,
invasion
RPS11: Ribosomal protein S11 3.99 0.000005 Antiapoptosis; selecting the correct tRNA in protein
biosynthesis
TPM4: tropomyosin 4 3.96 0.000159 stabilizing, repair and regeneration of cytoskeleton actin
filaments
SLC38A1: solute carrier family 38, member 1 3.85 0.000536 glutamine transporte; oxidative stress; detoxification
RPS20: ribosomal protein S20 3.83 0.012844 stabilize the folded structure of the ribosomal RNA
PSAT1: phosphoserine aminotransferase 1 3.83 0.000205 serine synthesis pathway; amino acid, phospholipid, and
nucleotide synthesis
LOX: lysyl oxidase 3.81 0.018453 crosslinking of collagens and elastin; tumor suppression
ACTR2: ARP2 actin-related protein 2 homolog (yeast) 3.74 0.005364 cell migration; cell polarity maintenance; asymmetric cell
division
DHX9: DEAH (Asp-Glu-Ala-His) box polypeptide 9 3.73 0.008356 DSB repair
HSP90B1: heat shock protein 90kDa beta (Grp94), member 1 3.61 0.001383 ER-associated protein degradation; unfolded protein response
NBPF family: neuroblastoma breakpoint family, members 3.57 0.000342 tumor suppressors linked to neuroblastoma
ATP13A3: ATPase type 13A3 3.56 0.002276 neuronal development; tumor suppressor
PPP1R3C: protein phosphatase 1, regulatory subunit 3C 3.55 0.019646 suppress glycogen breakdown; glycogen accumulation
FAM114A1: family with sequence similarity 114, member A1 3.54 0.020270 neuronal cell development
MATR3: matrin 3 3.50 0.001110 ATM target; DSB response; DSB repair; antiapoptosis
RASSF8: Ras association(RalGDS/AF-6) domain family 8 3.47 0.000865 adherens junction function; cell migration; tumor suppressor
UBA6: ubiquitin-like modifier activating enzyme 6 3.37 0.000331 activates ubiquitin and FAT10; proteasomal degradation
C6orf62: chromosome 6 open reading frame 62 3.29 0.002501 uncharacterized
PDLIM5: PDZ and LIM domain 5 3.16 0.001477 cytoskeleton organization; antiproliferation; heart development
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suggest a close link between lipid catabolism and stress-resistant
phenotype. Since resistant clones seem to favor FAO metabolism
as the main energy source, we hypothesized that resistant clones
may have higher levels of oxidative stress compared to sensitive
clones. Indeed, increased ROS production by resistant clones was
determined when compared to that of sensitive clones (Figure 6E).
These data therefore support the notion that increased oxidative
stress and fatty acid-supported mitochondrial respiration may
promote and maintain the stress-resistant phenotype of resistant
clones.
Upregulation of SIRT1-AMPK signaling, autophagic
activity, and global DNA repair transcripts in treatment-
resistant clones
It is well-documented that deacetylase SIRT1 is required for the
induction of a ‘‘longevity phenotype’’ by GR/CR [34,35], and it
has been suggested that CR activates AMPK, a metabolic fuel
gauge, which enhances SIRT1 activity by increasing cellular
NAD+ levels, resulting in the deacetylation of downstream SIRT1
targets that include PGC-1a, forkhead box O1 (FOXO1) and
FOXO3 [43]. Moreover, CR promotes cell survival via deacetyla-
tion of DNA repair factor Ku70 by SIRT1 [44], whereas loss of
SIRT1 impairs DNA damage response and reduces the ability to
repair DNA damage [45]. Likewise, autophagy is an essential part
of the anti-aging mechanism of CR [33]. It is a catabolic process
responsible for degrading damaged organelles and protein
aggregates via lysosomal degradation machinery and recycling
long-lived macromolecules for maintaining energy production
during nutrient stress. As anticipated, levels of NAD+ and
pAMPKa were higher in resistant clones compared to those in
sensitive clones (Figure 7A, 7B). However only the increase in RT-
resistant clones reached statistical significance. The upregulation
of pAMPKa expression in resistant clones was also demonstrated
by Western blot analysis, and that was accompanied by the
downregulation of pAkt when compared to sensitive clones
(Figure 7C). Higher autophagic activity was also detected in
resistant clones compared to sensitive clones (Figure 7D), while
activity was most enhanced in RT-resistant clones. Semi-qtRT-
PCR analysis revealed that most resistant clones have slightly
increased transcriptional levels of SIRT1 and its downstream
targets, PGC-1a, FOXO1, and FOXO3 transcription factors
when compared to autologous sensitive clones. Likewise, higher
transcriptional levels of Beclin-1 (BECN1) and microtubule-
associated protein 1 light chain 3 alpha (MAP1LC3A), two genes
which play a central role in autophagy, were also determined in
most resistant clones (Figure 7E). Correspondingly, transcriptional
levels of RAD51, Ku70, polymerase-b (POLB), and RAD23A
(detected by expression microarray), four genes that are known to
be involved in the repair of DSBs by homologous recombination
(HR), the repair of non-homologous end joining (NHEJ), base
excision repair (BER), and nucleotide excision repair (NER), were
all found to show some degree of upregulation in most resistant
clones when compared to autologous sensitive clones. Notably,
among the 4 DNA repair genes, RAD51 showed the highest extent
of upregulation in resistant clones (Figure 7E). Meanwhile, all
tested GSC clones expressed MGMT while only 2 out of 3
RT+TMZ-resistant clones expressed upregulated MGMT when
compared to that of autologous sensitive clones (Figure 7E).
Table 1. Cont.
Gene Name and Gene Symbol Fold Change P-Value Functional Involvement
RPL38: ribosomal protein L38 3.13 0.000001 translational control of Hox gene expression; tissue patterning;
antidifferentiation; antidevelopment
PRRG4: Proline rich Gla (G-carboxyglutamic acid) 4 3.08 0.012058 downregulates ERK K signaling; cell cycle control
MAP4: microtubule-associated protein 4 2.90 0.012801 stabilizes mitochondria, microtubule network, and viability
PRKCI: protein kinase C, iota 2.89 0.000997 antiapoptosis; survival; microtubule dynamics
RAB2A: RAB2A, member RAS oncogene family 2.88 0.004642 microtubule dynamics
SF3B1: splicing factor 3b, subunit 1,155kDa 2.87 0.001173 cell spliceosome; repression of Hox genes, antidifferentiation;
antidevelopment
RPL27A: Ribosomal protein L27a 2.77 0.000029 developmental patterning
HNRPA3: heterogeneous nuclear ribonucleoprotein A3 2.71 0.000016 stable maintenance of telomere repeats
BAT2D1: BAT2 domain containing 1 2.64 0.002660 cell cycle regulation
OSBPL8: oxysterol binding protein-like 8 2.48 0.000134 lipid receptors; modulate lipid homeostasis; suppress
cholesterol synthesis
MOBKL1B: MOB1, Mps One Binder kinase activator-like 1B 2.45 0.000767 growth control; tumor suppressor; antiapoptosis
RAD23A: RAD23 homolog A (S. cerevisiae) 2.41 0.000113 nucleotide excision repair; proteasomal degradation;
mitochondrial biogenesis
PPP2R1A: protein phosphatase 2, regulatory subunit A,
alpha
2.36 0.000030 DSB repair; impairs insulin action/glucose metabolism/Akt
activity; anti-growth; antiapoptosis
AGGF1: angiogenic factor with G patch and FHA domains 1 2.32 0.000417 Angiogenesis; vasculogenesis
FOLR1: folate receptor 1 (adult) 2.28 0.000301 DNA methylation; nucleotide synthesis; mitochondrial DNA
stability; DNA repair; regeneration of CNS
NOTE: Probe set signals on the expression array that were $2-fold increased in relative expression in treatment-resistant glioblastoma stem cell (GSC) clones (n = 6
clones from 3 patients; 3 RT-resistant clones and 3 RT+TMZ-resistant clones) compared with treatment-sensitive GSC clones (n = 6 clones from 3 patients) were selected.
Samples were permutated 100 times by dChip and identified 53 genes at false discovery rate (FDR) of ,0.1%. DSB =double-strand break; ER = endoplasmic reticulum;
ECM= extracellular matrix; DDR =DNA damage response; ATM=Ataxia telangiectasia mutated; ATR= Ataxia telangiectasia and Rad3 related; CNS = central nervous
system.
doi:10.1371/journal.pone.0080397.t001
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Molecular subclassification and genetic changes in
treatment-resistant GSC clones
Recent genomewide transcriptome analyses suggest that tumor
heterogeneity of glioblastoma tumors categorized into four clinical
subtypes also contain distinct GSC subtypes [46]. Since resistant
clones were selected via RT or RT+TMZ, it is possible that
radiation therapy may introduce genetic changes that contribute a
cause to explain the distinct properties in resistant clones. To
clarify this possibility, we performed an unsupervised sample
clustering using Freije et al. predictive 595 gene list [40], which
would allow for determining whether resistant clones maintain
glioma properties as well as which subtype they fall under. The
hierarchical clustering dendogram of sensitive and resistant clones
with prediction set of 595 genes showed hierarchical biclustering of
genes differentially expressed MES and PN subtype-associated
genes (C2 and C3) that segregated mesenchymal E445-RT/E445-
RT+TMZ from all the others that express PN-associated genes
(Figure 8). It is interesting to note that untreated E445 sensitive
clones was clustered as PN subtype distinct from autologous E445
resistant clones whereas that D431-resistant clones/D431-sensitive
clone were originated from MES tumor subtype. It has been
reported that MES-GSC and PN-GSC are two mutually exclusive
GSC subtypes with distinct dysregulated signaling pathways [46].
Unexpectedly, from the heatmap we also found two groups of
genes that were distinctively expressed between resistant clones
and sensitive clones; one group was downregulated and the other
group was upregulated in resistant clones when compared to
sensitive clones. The upregulated genes in resistant clones were
mostly associated with tumor suppressor, anti-growth, anti-
inflammation, anti-apoptosis, and cellular maintenance (Figure 8,
Table S4), therefore functionally similar to that of the molecular
signatures of resistant clones (Table 1). Conversely, the genes
down-regulated in resistant clones are those with a role in tumor
growth/progression, inflammation, extracellular remodeling, and
immune responses (Figure 8, Table S4). Moreover, since P53 is
known to be significantly mutated in PN subtype (54%) and in
MES subtype but with less frequency (32%) [41], we analyzed P53
status in sensitive and resistant clones. Homozygous mutations in
p53 with one gain-of-function mutation allele were detceted in all
tested resistant and sensitive clones (Figure S4A). Western blot
analysis further revealed that all tested clones express relatively
high levels of p53 protein except D431, but higher levels of
phosphorylated p53 (Ser-20) were determined in resistant clones
compared to those in sensitive clones after exposure to radiation (4
Gy) (Figure S4B). This data suggests the possibility that mutated
p53 may contribute to radiochemoresistance in resistant clones by
an unknown pathway that sensitive clones lack. Exome sequencing
Figure 5. Sensitization of radiation treatment by knockdown of selected molecular signatures of treatment-resistant GSC clones. A.
Cells derived from treatment-resistant GSC clones were treated with RT (12 Gy or 1.5 Gy) in the presence or absence of indicated siRNA targeting
selected signatures of resistant clones. Photos were taken 7 days after treatment. B. Verification of on-target gene knockdown by indicated siRNA
treatment. Total RNA from the resistant clones treated with specific siRNA was extracted. The mRNA expression levels of indicated genes were
analyzed by qtRT-PCR with specific primers. b-actin was used as an internal control gene.
doi:10.1371/journal.pone.0080397.g005
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analysis on a randomly selected coding regions (about 50Mb)
clearly showed somatic mutations introduced by the treatment as
anticipated (Figure S4C). These data thus suggest that although
therapy have introduced additional genetic mutations in resistant
clones, these resistant clones still maintain glioblastoma properties
(also was proven by the histopathologic features of tumor in
animals) and support the view that the resistant clones were
generated by the clonal selection for those possessing cellular
quiescence with stress resistance phenotype.
Discussion
In this study, we seek the cellular and molecular basis of
glioblastoma resistance to standard treatment. We isolated and
characterized tumorigenic GSC clones that survived RT and
RT+TMZ. We found that the majority of tumorigenic GSC clones
derived from patient tumors are sensitive to treatment, and only a
minority of clones is able to survive treatment. Importantly, we
found that although cells repopulated from resistant clones are still
sensitive to treatment, repeated treatment could promote the
expansion of resistant clones. This may suggest the hierarchy of
resistant clones. If it is true that GSC are slow-cycling and
radiochemoresistant, then sensitive clones may represent a more
differentiated progeny derived from resistant clones. This notion is
supported by a recent study which demonstrated a hierarchy of
self-renewing tumor-initiating cell type in glioblastoma and
suggested that the capacities for tumor initiation need not be
restricted to a uniform population of GSC [47]. Despite preserving
tumorigenic potential, sensitive clones have lost stress resistance,
which is likely due to undergoing proliferative differentiation and
losing quiescent status as evidenced by downregulation of stem cell
markers and shortening of cell cycle length. By contrast, the slower
cell cycle progression in resistant clones may permit repair prior to
cell division. Although CD133 may not be an obligated marker for
GSC, our data support the view that it may be a marker for GSC
Figure 6. Treatment-resistant GSC clones use fatty acid oxidation (FAO), not glycolysis, as an essential energy source for
maintaining intracellular ATP levels. A. Intracellular ATP levels of treatment-resistant clones and treatment-sensitive clones were measured
using a luciferin–luciferase-based bioluminescence assay. Prior to assay, cells were treated with a glycolytic inhibitor (2-DG), a mitochondrial
glutamine transport inhibitor (L-histidine), and a FAO inhibitor (Etomoxir), respectively, in a dose-escalating fashion as indicated. Cells without
treatment served as controls. Luminescent intensity was measured by a luminescence microplate reader. B. Microscopic morphology of
representative sensitive clones and resistant clones treated with indicated inhibitor. Magnification, 5X (a–d, f–i, k–n) and 20X (e, j, o). C. Glucose
uptake by resistant clones and sensitive clones was measured by exposing cells to a fluorescently-labeled deoxyglucose analog (2-NBDG) in the
presence of insulin. Mean fluorescence intensity was determined by flow cytometric analysis. Data represent mean values 6 SD of triplicate dishes.
*p,0.05 versus sensitive clones. D. Endogenous levels of phosphorylated of Akt at Thr308 was detected by a Phospho-Akt (Thr308) ELISA Kit. Seventy
micrograms of cell lysates from each sample was used in the assay. The magnitude of the absorbance for the developed color is proportional to the
quantity of Akt phosphorylated at Thr308. Data represent mean values 6 SD of 3 clones, which are derived from 3 patients, in triplicate wells.
*p,0.05 versus sensitive clones. E. Reactive oxygen species (ROS) generation by sensitive clones and resistant clones was measured using
dichlorofluorescein diacetate (DCF-DA), which transforms to fluorescence by interacting with oxidants. Prior to measurement, cells were treated with
or without 5 mM Tiron. ROS production was assayed by flow cytometric analysis.
doi:10.1371/journal.pone.0080397.g006
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with treatment-resistant phenotype [9]. Thus, the existence of
quiescent, treatment-resistant GSC clones may explain that cancer
treatment with a new drug targeting the proliferative population
will always lead to the emergence of resistance. Moreover,
increasing number of treatment cycles will further enrich resistant
clones, by which more resistant tumor-initiating cells will
accumulate, leading to an aggressive, untreatable tumor in a
short period of time. Although clinically relevant dosages of TMZ
have effects in treatment of glioblastoma tumors, we did not
observe any obvious treatment benefits when incorporated with
RT in our GSC model. This may be due to our study only
focusing on the stem-like cells which all express MGMT in our
model.
Figure 7. Regulation of cellular and molecular activities associated with metabolic adaptation to reduced glucose usage in
treatment-resistant GSC clones. A. Intracellular NAD+ levels in sensitive clones and resistant clones (104 cells/well) were determined by a NAD+/
NADH colorimetric assay kit. The amount of NAD+ in cell lysate was quantified by comparing with NAD+/NADH standard solutions. B. Endogenous
levels of pAMPK in resistant clones and sensitive clones were determined by a phospho-AMPKa (Thr172) ELISA Kit. Seventy micrograms of cell lysates
from each sample were used in the assay. The magnitude of the absorbance for the developed color is proportional to the quantity of AMPKa
phosphorylated at Thr172. C. Representative image of Western blot analysis of AMPKa, phospho-AMPKa (Thr172), Akt, phospho-Akt (Thr308), or b-
actin expressed in sensitive clones and resistant clones. D. GSC autophagy is measured with a fluorescent acidotropic dye and flow cytometry based
on a correlation between autophagic activity and overall lysosomal acidity. The intensity of lysosomal staining is proportional to lysosomal acidity.
Data in A, B, and D represent mean values 6 SD of 3 clones, which are derived from 3 patients, in triplicate wells. *p,0.05 versus sensitive clones.
E.The mRNA expression levels of indicated genes were analyzed by semi-qtRT-PCR with specific primers. b-actin was used as an internal control gene.
doi:10.1371/journal.pone.0080397.g007
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Treatment-resistant GSC clones appear to possess both anti-
aging (stem-like cells) and superior stress resistance (resistance to
radiochemotherapy) properties, and the close link between these
two properties has been well-demonstrated in the naked mole-rat,
the longest-living rodent [48]. To explore the protective strategies
which drive the super-survivability of resistant clones, we
performed a comparative analysis of genome-wide gene expression
profiles in resistant clones and sensitive clones, as such will allow
for discovery of molecular signatures and regulatory mechanisms
operated in resistant clones that are not or less activated in
sensitive clones, in an unbiased and comprehensive fashion.
Surprisingly, molecular signatures of resistant clones portrayed an
GR-induced ‘‘anti-stress’’ phenotype [26-33] and these results
were further supported by the outcome of non-suprevised sample
profiling using prediction set of 595 gene hierarchical clustering,
which also unexpectedly identified the similar molecular properties
in resistant clones. Both profiles portray a quiescent status of
resistant clones by upregulation of genes associated with anti-
growth, anti-differentiation, anti-inflammation, and tumor sup-
pressor phenotype, which was also found in mouse tissue response
to CR [49]. The siRNA knockdown experiment further suggested
the importance of defense signatures of resistant clones and
highlight the potential link between the metabolic transformation
and radiochemoresistance. The induction of autophagy by
radiation contributing to radioresistance has been demonstrated
in GSC system [50]. Likewise, an increased expression of the
glucose deprivation response network was also identified in breast
cancer cells resistant to lapatinib, suggesting resistant cells are
under nutrient stress mode [51]. Although a recent study indicated
that short-term starvation can augment the efficacy of standard
treatment (RT+TMZ) for glioma in the aggressive murine models
of glioblastoma [52], it did not conflict with our study results since
GR may enhance host’s stress resistance against disease. More-
over, we also demonstrated that sensitive clones and its derived
progeny (fast-growing cells) are sensitive to GR, and only resistant
clones remain independent from glucose. This observation
suggests that resistant clones may use a GR-like mode to maintain
their cellular quiescence and force cells to switch on lipid
catabolism and autophagy for energy source and subsequently
activate maintenance and repair machinery for survival. Resistant
clones were clonally derived from the patient tumor-derived
CD133+ GSC cultures or from clonogenic cell-derived treatment-
resistant clones by in-vitro treatment selection (treatment cycle 1
and 2), thus implying intratumoral heterogeneity and a GSC
hierarchy, which could be revealed via treatment selection because
of their differential treatment sensitivity. It is possible that GSC
with a GR-like phenotype (resistant clones) are pre-existent
quiescent cells in tumor for guarding the ‘‘tumor tissue’’ [53].
Figure 8. Molecular subclassification of treatment-sensitive and treatment-resistant GSC clones. Non-supervised hierarchical clustering
of sensitive clones and resistant clones with prediction set of 595 genes. The heatmap with dendrogram showed hierarchical biclustering of genes
differentially expressing mesenchymal subtype-associated genes and proneural subtype-associated genes which segregated treatment-sensitive and
resistant GSC clones of E445 (C3) from all the others (C2). Genes distinctly expressed between sensitive clones and resistant clones were also
identified (C1a, C1b, and C4).
doi:10.1371/journal.pone.0080397.g008
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Although additional mutations were introduced by the treatment,
they continue to produce sensitive and resistant clonogenic cells,
and initiate a tumor with pathophysiologic features similar to the
one initiated by sensitive clones, implying that they were unlikely
solely selected through the reprogramming by the DNA-damaging
agents [54].
The expression microarray data combined with functional
assays support the view that radiochemoresistance of resistant
clones may be associated with the activation of the SIRT1
signaling pathway, autophagy, and a global DNA repair response
induced by GR-like metabolic status/adaptation, by which
resistant clones reinforce cellular and genomic integrity against
deadly stress. SIRT1 promotes autophagy and DNA repair
activity, and maintains genomic stability [43-45]. It has been
reported that SIRT1 contributes to telomere maintenance and
increases global homologous recombination [55]. Thus, our
detection of increased transcriptional levels of RAD51 in resistant
clones may imply that the maintenance of telomere length and
integrity is part of the defense system. Correspondingly, a 6-fold
increase in transcriptional levels of early growth response-1
(EGR1) was detected in resistant clones (Table 1), and it has been
shown that EGR1 promotes autophagy [56] and is required for
transcription activation of SIRT1 to stimulate the expression of
manganese superoxide dismutase, an antioxidant enzyme that
contributes to ROS scavenging [57].
In summary, our data suggest that the emergence of radio-
chemoresistance may arise from the selection and expansion of
quiescent GSC clones expressing GR-associated stress-resistant
phenotype. Reduced glucose uptake by resistant clones may
transform the metabolic adaptation of genome, leading to the
constitutive activation and amplification of repair programs, which
form the critical basis of radiochemoresistance. Even though
radiochemotherapy could introduce additional gene mutations,
molecular properties of glioblastoma origin were preserved,
therefore allowing for regeneration of brain tumors in animals
exhibited histopathological features similar to human glioblasto-
ma. Direct isolation of GSC clones with GR phenotype from
treated and recurred tumors would provide better evidence and a
better study model since extrinsic cues from their niche may
provide vital signaling for further modulating molecular properties
and pathophysiology that contribute to treatment resistance. Our
data support the view that the novel combination of standard
treatment and a therapeutic strategy targeting the metabolic stress-
induced adaptation resistance, may prevent treatment-resistant
GSC clone-mediated tumor recurrence.
Supporting Information
Figure S1 In vitro treatment of GSC cultures consisting of
fractionated irradiation with or without temozolomide (TMZ).
GSC received (A) radiation treatment (RT) alone (4 Gy on day 1,
day 4, and day 7) or (B) concomitant TMZ (5 mM) and RT
followed by adjuvant TMZ treatment (10 mM) for an additional 4
days after a 2-day break. The cell populations that formed colonies
after the treatment were counted on day 14.
(TIF)
Figure S2 Treatment-resistant GSC clones contain a heteroge-
neous population. A. Replating cells derived from single cell-
derived resistant clones showed increased clonogenic cells capable
of self-renewal, proliferative differentiation and migration. B.
Re-treatment of cells dissociated from a single resistant clone
(E445-RT+TMZ) identified treatment-sensitive clonogenic cells
(majority), treatment-resistant clonogenic cells (minority) and non-
proliferative single cells (a–b). Clonogenic survivors slowly regain
their capability to repopulate progeny and migrate outward from
tumor spheres (c–f).
(TIF)
Figure S3 Molecular signatures and defense profiles of treat-
ment-resistant GSC clones. A. All plots show normalized gene
expression values converted into a heat map. The log2 of the fold
difference is indicated by the heat map scale at the bottom. Each
column is an individual sample organized into cell types and
selection conditions as indicated at the top. Each row is a single
probe set measurement of transcript abundance for an individual
gene. Probe set signals on the expression array that were $2-fold
increased in relative expression in treatment-resistant GSC clones
compared with treatment-sensitive GSC clones. Samples were
permutated 100 times by dChip and identified 53 genes (Table 1
in text) at false discovery rate (FDR) of ,0.1%. B. Verification of
gene expression in A. Total RNA from the indicated cells were
extracted. The mRNA expression levels of indicated genes were
analyzed by qtRT-PCR with specific primers. GAPDH was used
as an internal control gene.
(TIF)
Figure S4 Genetic mutations in treatment-sensitive and treat-
ment-resistant GSC clones. A. Somatic variations in TP53. B.
Western blot analysis of p53. C. Count of mutations introduced by
treatment with RT or RT+TMZ.
(TIF)
Table S1 Primer sequences and product sizes for semi-qtRT-
PCR analysis.
(DOCX)
Table S2 Genes expressed at higher levels in RT-resistant GSC
clones compared with treatment-sensitive GSC clones.
(DOCX)
Table S3 Genes expressed at higher levels in RT+TMZ-
resistant GSC clones compared with treatment-sensitive GSC
clones.
(DOCX)
Table S4 Distinct gene expressions in treatment-resistant GSC
clones compared to treatment-sensitive GSC clones identified
from predictive 595 genes.
(DOCX)
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